GlassScriptPhysician profile
Tsilya Bass
NPI 1841330800
$73,752.68
in general payments reported to CMS, 2019-2025
29 companies · $7,694 in 2025
The $7,694 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,209 · 2021: $10K · 2022: $6,223 · 2023: $17K · 2024: $8,709 · 2025: $7,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $6,473 · Travel and Lodging: $316 · Education: $24.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,250.00 |
| Food and Beverage | $6,473.23 |
| Travel and Lodging | $315.81 |
| Education | $24.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41,852.03 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Allergan, INC. | $10,438.28 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $8,742.35 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,715.61 | 2019-2022 | |
| Eisai INC. | $1,813.26 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,018.59 | 2021-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $861.12 | 2019-2022 | |
| Alkermes, INC. | $848.12 | 2021-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $724.44 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $633.88 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $621.19 | 2019-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $612.28 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $385.90 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $246.67 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $211.69 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $189.98 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $166.07 | 2023-2025 | Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $157.86 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $120.00 | 2019-2023 | Belsomra |
| Teva Pharmaceuticals USA, INC. | $113.89 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $59.60 | 2024-2025 | Invega Sustenna |
| Corium, LLC | $52.86 | 2023 | Adlarity |
| Biohaven Pharmaceuticals, INC. | $40.85 | 2021 | |
| Pfizer INC. | $35.73 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | Rexulti |
| Ucb, INC. | $18.60 | 2020 | |
| Redhill Biopharma INC. | $17.55 | 2020 | |
| Tonix Medicines, INC. | $15.45 | 2025 | Tonmya |
| Arbor Pharmaceuticals, INC. | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tsilya Bass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.